Investing.com - Landos Biopharma reported on Thursday third quarter earnings that beat analysts' forecasts and revenue that was inline with expectations.
Landos Biopharma announced earnings per share of $-0.20 on revenue of $0.00. Analysts polled by Investing.com anticipated EPS of $-0.28 on revenue of $0.00.
Landos Biopharma shares are down 4.96% from the beginning of the year and are trading at $0.26 , down-from-52-week-high.
Landos Biopharma shares gained 13.91% in intra-day trade the report.
Landos Biopharma follows other major Healthcare sector earnings this month
Landos Biopharma's report follows an earnings beat by UnitedHealth on October 14, who reported EPS of $5.79 on revenue of $80.89B, compared to forecasts EPS of $5.43 on revenue of $80.52B.
J&J had beat expectations on October 18 with third quarter EPS of $2.55 on revenue of $23.79B, compared to forecast for EPS of $2.52 on revenue of $23.46B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar